Discovery of 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase

被引：429

作者：

Sun, L ^{[1
]}

Liang, C ^{[1
]}

Shirazian, S ^{[1
]}

Zhou, Y ^{[1
]}

Miller, T ^{[1
]}

Cui, J ^{[1
]}

Fukuda, JY ^{[1
]}

Chu, JY ^{[1
]}

Nematalla, A ^{[1
]}

Wang, XY ^{[1
]}

Chen, H ^{[1
]}

Sistla, A ^{[1
]}

Luu, TC ^{[1
]}

Tang, F ^{[1
]}

Wei, J ^{[1
]}

Tang, C ^{[1
]}

机构：

[1] Sugen Inc, San Francisco, CA 94080 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2003年 / 46卷 / 07期

关键词：

D O I：

10.1021/jm0204183

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To improve the antitumor properties and optimize the pharmaceutical properties including solubility and protein binding of indolin-2-ones, a number of different basic and weakly basic analogues were designed and synthesized. 5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl- 1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide (12b or SU11248) has been found to show the best overall profile in terms of potency for the VEGF-R2 and PDGF-Rbeta tyrosine kinase at biochemical and cellular levels, solubility, protein binding, and bioavailability. 12b is currently in phase I clinical trials for the treatment of cancers.

引用

页码：1116 / 1119

页数：4

共 12 条

[1] New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
Cherrington, JM
Strawn, LM
Shawver, LK
[J]. ADVANCES IN CANCER RESEARCH, VOL 79, 2000, 79 : 1 - 38
[2] VEGF: an update on biological and therapeutic aspects
Farrara, N
[J]. CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (06) : 617 - 624
[3] Fong TAT, 1999, CANCER RES, V59, P99
[4] Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
Gale, NW
Yancopoulos, GD
[J]. GENES & DEVELOPMENT, 1999, 13 (09) : 1055 - 1066
[5] Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
Hennequin, LF
Stokes, ESE
Thomas, AP
Johnstone, C
Plé, PA
Ogilvie, DJ
Dukes, M
Wedge, SR
Kendrew, J
Curwen, JO
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) : 1300 - 1312
[6] Laird AD, 2000, CANCER RES, V60, P4152
[7] Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
Liao, AT
Chien, MB
Shenoy, N
Mendel, DB
McMahon, G
Cherrington, JM
London, CA
[J]. BLOOD, 2002, 100 (02) : 585 - 593
[8] Mendel DB, 2003, CLIN CANCER RES, V9, P327
[9] MENDEL DB, 2002, AM ASS CANC RES
[10] Evidence for distinct signaling properties and biological responses induced by the PDGF receptor α and β subtypes
Rosenkranz, S
Kazlauskas, A
[J]. GROWTH FACTORS, 1999, 16 (03) : 201 - 216

← 1 2 →